Vaxzevria (previously COVID-19 Vaccine AstraZeneca): contraindication in individuals with previous capillary leak syndrome

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Active substance
ChAdOx1-SARS-COV-2
Therapeutic area (MeSH)
COVID-19 virus infection
Regulatory outcome
Variation
DHPC type
Safety signal
Human ATC code
J07BX03
Dissemination date
23/06/2021

How useful was this page?

Add your rating